Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-weekly NNC0519-0130 in adults with overweight or obesity (dose-finding phase 2)
jRCT2051230198Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2024
- Modality
- Small Molecules, Peptides
01
Overview
Phase 2, randomised, double-blind trial of NNC0519-0130 in obesity and Overweight (3 arms), sponsored by Novo Nordisk. Primary endpoint: Change from baseline in body weight (%). Started Mar 2024; status: completed.
02
Drugs
NNC0519-0130
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on jRCT2051230198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230198.